TABLE 1.
Basic parameters in the experimental groups.
| Parameters | Sham | UUO | UUO + Dapa | UUO + Nec-1 | UUO + GSK872 |
|---|---|---|---|---|---|
| ΔBW (g) | 57 ± 2.7 | 38 ± 6.5* | 40 ± 5.2* | 37 ± 7.8* | 40 ± 3.1* |
| WI (ml) | 23 ± 1.8 | 25 ± 3.2 | 38 ± 2.7* | 27 ± 3.0 | 21 ± 9.4 |
| UV (ml) | 18 ± 2.5 | 21 ± 1.9 | 35 ± 1.4* | 23 ± 3.4 | 25 ± 2.6 |
| FG (mg/dl) | 107.0 ± 8.2 | 103.2 ± 11.5 | 91.2 ± 3.2 | 100.0 ± 6.1 | 92.1 ± 5.2 |
| HbA1c (%) | 3.6 ± 0.01 | 3.5 ± 0.03 | 3.8 ± 0.12 | 3.6 ± 0.04 | 3.4 ± 0.02 |
| TG (mg/dl) | 82.7 ± 17.5 | 78.3 ± 24.9 | 82.4 ± 20.1 | 76.6 ± 16.1 | 89.3 ± 15.4 |
| CHO (mg/dl) | 66.0 ± 4.6 | 71.0 ± 7.5 | 62.9 ± 8.6 | 64.5 ± 8.0 | 64.3 ± 3.6 |
| HDL-C (mg/dl) | 11.2 ± 0.7 | 12.3 ± 0.3 | 10.6 ± 0.8 | 10.2 ± 1.0 | 9.8 ± 2.0 |
| LDL-C (mg/dl) | 14.2 ± 1.1 | 16.5 ± 0.9 | 14.4 ± 1.6 | 15.5 ± 1.6 | 13.9 ± 0.8 |
| hsCRP (mg/dl) | 0.20 ± 0.03 | 0.21 ± 0.02 | 0.20 ± 0.03 | 0.18 ± 0.06 | 0.21 ± 0.04 |
| UPE (mg/L) | 318.8 ± 35.1 | 289.1 ± 40.6 | 319.0 ± 49.6 | 300.7 ± 38.7 | 301.8 ± 38.0 |
| Scr (mg/dl) | 0.30 ± 0.01 | 0.35 ± 0.02 | 0.28 ± 0.03 | 0.32 ± 0.02 | 0.34 ± 0.04 |
| BUN (mg/dl) | 132.8 ± 5.2 | 143.6 ± 12.3 | 139.3 ± 16.4 | 128.7 ± 9.0 | 142.5 ± 14.5 |
| Cys-c (mg/L) | 3.0 ± 0.20 | 2.9 ± 0.08 | 3.1 ± 0.13 | 2.8 ± 0.13 | 3.2 ± 0.16 |
Values are presented as mean ± SEM. UUO, unilateral ureteral obstruction; Dapa, dapagliflozin; Nec-1: necrostatin-1; ΔBW: body weight gain; WI: water intake; UV: urine volume; FG: fasting glucose; TG: triglyceride; CHO: cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; hsCRP: high sensitivity C-reactive protein; UPE, urine protein excretion; Scr, serum creatinine; BUN, blood urea nitrogen; CysC, cystatin C. * p < 0.05 vs sham.